ClinicalTrials.gg
Sign In
Drug

SHP2 Inhibitor ERAS-601 clinical trials

Also written ERAS-601.

studies test it
4
open now
0
in phase 3
0
first study started
2020

How each study uses SHP2 Inhibitor ERAS-601 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

ERAS-601
4

Studies by the year they started

4 studies that test it; most in 2020 (1)

Studies that test SHP2 Inhibitor ERAS-601, by start year
YearStudies
20201
20211
20221
20251

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Chordoma
1
Leukemia, Myeloid, Acute
1

Who runs them

Industry 3 · Other 1

Erasca, Inc. (3) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

ASN-007 (2) · Sotorasib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test SHP2 Inhibitor ERAS-601.

Studies

Open first, then newest update. How each study uses SHP2 Inhibitor ERAS-601 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Given beside what is tested · 1 — SHP2 Inhibitor ERAS-601 is usual care or a partner of the new treatment